Substrate-dependent modulation of CYP3A4 catalytic activity: Analysis of 27 test compound's with four fluorometric substrates

Drug Metabolism and Disposition

Volumn 28, Issue 12, 2000, Pages 1440-1448

  Stresser, David M ^a   Blanchard, Andrew P ^a   Turner, Stephanie D ^a   Erve, John C L ^a   Dandeneau, Andre A ^a   Miller, Vaughn P ^a   Crespi, Charles L ^a  

^a Gentest Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 BENZYLOXY 4 TRIFLUOROMETHYLCOUMARIN; 7 BENZYLOXYQUINOLINE; BENZYLOXYRESORUFIN; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DIBENZYLFLUORESCEIN; MIDAZOLAM; NIFEDIPINE; TESTOSTERONE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; DEALKYLATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; FLUOROMETRY; KINETICS; PRIORITY JOURNAL;

ALGORITHMS; CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; FLUORESCENT DYES; GABA MODULATORS; HUMANS; KINETICS; MASS SPECTROMETRY; MIDAZOLAM; MIXED FUNCTION OXYGENASES; NIFEDIPINE; SPECTROMETRY, FLUORESCENCE; SPECTROPHOTOMETRY, ULTRAVIOLET; TESTOSTERONE;

EID: 0033664783     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole
2. Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe
3. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
4. Microtiter plate assays for inhibition of human, drag-metabolizing cytochromes P450
5. Effect of inhibitor depletion on inhibitory potency: Tight binding of CYP3A by clotrimazole
6. Role of cytochrome P450 enzymes in drug-drug interactions
7. Analysis of human cytochrome P450 3A4 cooperativity: Construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics
8. Part II. Cytochrome P450 families/subfamilies
9. CYP3A4 drug interactions: Correlation of 10 in vitro probes substrates
10. CO binding kinetics of human cytochrome P450 3A4. Specific interaction of substrates with kinetically distinguishable conformers
11. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to the cytochrome P450 active sites
12. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4
13. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: Assessment of human CYP inhibition potential
14. P450 Enzymes. Inhibition mechanism, genetic regulation and effects of liver disease
15. Nonspecific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine and propranolol
16. (O-methyl C-14)naproxen O-demethylase activity in human liver microsomes-evidence for the involvement of cytochrome P4501A2 and P4502C9/10
17. 14C]-dextromethorphan
18. [O-Ethyl 14C]Phenacetin O-deethylase activity in human liver microsomes
19. Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone
20. Inter/ndividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
21. Cooperativity in oxidation catalyzed by cytochrome P450 3A4
22. Human cytochrome P-450 3A4 in vitro drug-drug interaction patterns are substrate-dependent
23. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen
24. Identification of the pharmacogenetic determinants of alfentanil metabolism: Cytochrome P-450 3A4